Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312801 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
A Phase 1 study of Lymphoma, Non-Hodgkin Lymphoma, B-Cell, sponsored by Luminary Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT05312801 is a Phase 1 study of Lymphoma, Non-Hodgkin Lymphoma, B-Cell that is actively recruiting participants, run by Luminary Therapeutics. The registered enrollment target is 20 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT05312801, a Phase 1 study of Lymphoma, Non-Hodgkin Lymphoma, B-Cell, is actively recruiting participants, sponsored by Luminary Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non-Hodgkin lymphoma using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.
Conditions Studied
Interventions
- DRUG BAFF CAR-T
Study Locations (2)
Ohio
- University Hospitals Seidman Cancer Center - Cleveland
- Taussig Cancer Institute | Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2025-09-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05312801
The ClinicalTrials.gov registry entry for NCT05312801 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Luminary Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma, Non-Hodgkin Lymphoma, B-Cell appearing as the primary indexed condition, and to 1 intervention - of which BAFF CAR-T is the first listed.
NCT05312801 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05312801 about?
NCT05312801 is a clinical study titled "Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma". Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractor...
What is the current status of trial NCT05312801?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-11-21. Estimated completion is 2025-09-02.
What conditions does trial NCT05312801 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin Lymphoma, B-Cell.
What interventions are being tested in trial NCT05312801?
The interventions under investigation include: BAFF CAR-T (DRUG).
Who is sponsoring clinical trial NCT05312801?
This trial is sponsored by Luminary Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05312801 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.